Viral hepatitis C liquid calibrator diluent and viral hepatitis C detection kit

Through the composition and combination of liquid calibration product diluents, the problems of high production cost and complex use of lyophilized products are solved, and the detection results with high stability and accuracy are achieved, and the production and use process is simplified.

CN118961340APending Publication Date: 2024-11-15SHENZHEN AIVD BIOTECH INC
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411085505.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing calibration quality control products for type C viral hepatitis are freeze-dried products, which are costly and complex to use, which affects the accuracy of the test results.

Method used

Provide a liquid calibration product diluent for type C viral hepatitis, containing buffer, 2-morpholine ethanesulfonic acid, protein protector, non-reducing disaccharides, amino acids and bovine serum, through a specific composition ratio and pH combination, Form a stable system, simplify production processes and improve the stability of the calibration products.

Benefits of technology

Reduce production costs, simplify the use process, avoid the impact of human operation on the results, improve the accuracy of the detection results, and store the signal retention rate for 7 days at 37℃. 2- It was stored stably for 12 months under 8℃.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses a viral hepatitis C liquid calibrator diluent and a viral hepatitis C detection kit, and relates to the technical field of biological detection. The viral hepatitis C liquid calibrator diluent provided by the invention is obtained by compounding 2-morpholinoethanesulfonic acid, a protein protective agent, non-reducing disaccharide, amino acid and bovine serum in a buffer system, the components cooperate with each other and play roles, and the obtained calibrator diluent has the advantage of high stability, and is suitable for clinical application. The viral hepatitis C antigen can be stably stored (in a liquid state) in the calibrator diluent provided by the invention; freeze-drying is not needed in the production process, so that the production process is simplified, and the production cost of enterprises is reduced; and redissolution is not needed during use, so that clinical use is more convenient, the influence of manual operation on a result is avoided, and a test result is more accurate. The viral hepatitis C liquid calibrator provided by the invention has the advantage of high stability, and can be used for preparing a viral hepatitis C detection kit.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biological detection, and in particular to a hepatitis C virus liquid calibrant diluent, a calibrant containing the diluent, and a hepatitis C virus detection kit. Background Art

[0002] Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily causes liver damage. About 75% to 85% of people with acute HCV infection will develop chronic HCV infection, which can lead to chronic hepatitis and liver fibrosis, and some patients may develop cirrhosis or even hepatocellular carcinoma.

[0003] Hepatitis C is an infectious disease that is mainly transmitted through blood and sex. According to WHO statistics, since the discovery of Hepatitis C Virus (HCV) in 1989, about 170 to 200 million people worldwide have been infected with HCV. The peak period of hepatitis C infection in my country was from the late 1980s to the early 1990s. Epidemiological surveys show that the HCV antibody positivity rate in the Chinese population is about 3.2%. HCV is an enveloped single-stranded positive-strand RNA virus. It is currently classified as a member of the Flaviviridae family and the Hepatitis C virus genus. It is mainly transmitted through blood and sex. About 50% to 85% of hepatitis caused by HCV can develop into chronic hepatitis, of which about 10% to 30% develop into cirrhosis, and about 3% to 10% of patients with cirrhosis can develop into hepatocellular carcinoma. HCV initial infection is often relatively hidden, and only about 20% to 30% of infected people show symptoms of acute hepatitis, so it is very important to choose an ideal detection method to detect HCV in a timely manner.

[0004] Hepatitis C virus (HCV) is a chronic hepatotropic virus that develops insidiously and has atypical clinical manifestations. Clinical diagnosis and efficacy observation rely on laboratory test results. Currently, clinical diagnosis is mainly made by detecting HCV antibodies (Anti-HCV). However, after HCV infection, anti-HCV appears slowly, and the serological conversion of general antibodies can be delayed until several months after exposure, which is easy to miss. It is reported that HCV core antigen detection can be 23 to 46 days earlier than HCV antibody detection, and can be used for early diagnosis before HCV infection seroconversion.

[0005] Currently, most of the calibration quality control products for hepatitis C virus detection kits on the market are freeze-dried products, which have complex preparation processes and high storage and transportation conditions. In addition, most freeze-drying instruments on the market are expensive, which increases the production costs of companies. There are many inconveniences in the clinical use of freeze-dried products. They need to be manually reconstituted and the containers need to be replaced for testing. The reconstitution is greatly affected by human factors and can easily lead to certain deviations in the results. In addition, the freeze-dried products are not easy to preserve after reconstitution. Summary of the invention

[0006] The technical problem to be solved by the present invention is that the existing hepatitis C virus calibration quality control products are freeze-dried products, which have high production costs and are complicated to use, thus affecting the accuracy of the test results.

[0007] In order to solve the above problems, the present invention proposes the following technical solutions:

[0008] In a first aspect, the present invention provides a hepatitis C virus liquid calibrator diluent, comprising the following components:

[0009] 40-60mmoL / L buffer, 5.3-10.6g / L 2-morpholineethanesulfonic acid, 20-40% (v / v) protein protectant, 20-50g / L non-reducing disaccharide, 20-50g / L amino acid, 5-10% bovine serum.

[0010] Furthermore, the protein protectant includes AP-Protector.

[0011] Furthermore, the buffer is selected from at least one of PB buffer or sodium citrate buffer.

[0012] Furthermore, the non-reducing disaccharide includes sucrose, lactose, maltose, and trehalose. Trehalose is preferred because it has a higher glass transition temperature and is easier to form a glassy state, supporting and wrapping protein molecules to prevent them from denaturing.

[0013] Furthermore, the bovine serum is selected from fetal bovine serum.

[0014] Furthermore, the invention also comprises 0.05-0.1% by volume of a nonionic surfactant and 0.05-0.2% by volume of a preservative.

[0015] Furthermore, the nonionic surfactant is selected from at least one of Tween 20 and Triton 100.

[0016] Furthermore, the pH of the hepatitis C virus liquid calibrator diluent is 7.0-8.0.

[0017] Furthermore, the pH of the hepatitis C virus liquid calibrator diluent is 7.2-7.8.

[0018] Furthermore, the pH of the hepatitis C virus liquid calibrator diluent is 7.4±0.05.

[0019] In a second aspect, the present invention provides a method for preparing a hepatitis C virus liquid calibrator diluent as described in the first aspect, characterized in that it comprises dissolving and mixing the components in proportion, and after mixing, diluting the volume to the prepared amount with purified water, and filtering using a filter membrane with a pore size of 0.2-0.5 μm to obtain the hepatitis C virus liquid calibrator diluent.

[0020] Furthermore, the filter membrane is a nylon filter membrane.

[0021] Furthermore, the preparation method also includes adjusting the pH of the system with hydrochloric acid solution or sodium hydroxide solution.

[0022] In a third aspect, the present invention provides a liquid calibrator for hepatitis C virus, characterized in that it comprises a hepatitis C antigen and the hepatitis C virus liquid calibrator diluent described in the first aspect or the hepatitis C virus liquid calibrator diluent obtained by the preparation method described in the second aspect.

[0023] In a fourth aspect, the present invention provides a hepatitis C virus detection kit, comprising the hepatitis C virus liquid calibrator described in the third aspect.

[0024] Furthermore, the kit is a kit that uses chemiluminescence for detection.

[0025] Compared with the prior art, the technical effects achieved by the present invention include:

[0026] The hepatitis C virus liquid calibrant diluent provided by the invention is obtained by compounding 2-morpholineethanesulfonic acid, a protein protective agent, a non-reducing disaccharide, an amino acid and bovine serum in a buffer system, and the components cooperate with each other to play a role. The obtained calibrant diluent has the advantage of high stability, and the hepatitis C virus antigen can be stably preserved (in liquid state) in the calibrant diluent of the invention; the production process does not need to be freeze-dried, the production process is simplified, and the production cost of the enterprise is reduced; when used, no redissolution is required, so that clinical use is more convenient, the influence of human operation on the result is avoided, and the test result is more accurate.

[0027] In the calibration diluent of the present invention, under the condition of a phosphoric acid or citric acid buffer system with a certain pH value, the combination of a protein protectant with 2-morpholineethanesulfonic acid, bovine serum, a non-reducing disaccharide and an amino acid in a specific ratio greatly improves the stability of the system; 2-morpholineethanesulfonic acid has excellent buffering capacity and chemical stability, and the sulfonic acid group in its molecular structure also provides it with higher water solubility, so that it can be better dissolved in an aqueous solution, thereby improving the stability and solubility of the buffer solution; sugar molecules usually have more than 5 hydroxyl groups, can form hydrogen bonds with proteins to replace water, and ensure the stability of the protein; and the simultaneous addition of amino acids, bovine serum and the like in the system plays a role in jointly improving the stability of the system.

[0028] The hepatitis C virus liquid calibrator provided by the present invention has been experimentally verified to be able to achieve a signal retention rate of 90%-110% when placed at 37°C for 7 days; and can be stably stored for 12 months under 2-8°C sealed conditions, and has the advantage of high stability.

[0029] The hepatitis C virus detection kit provided by the present invention adopts chemiluminescence method for detection, contains the hepatitis C virus liquid calibrator provided by the present invention, can be directly detected, simplifies the detection operation, and helps to improve the accuracy of the detection result. DETAILED DESCRIPTION

[0030] The technical solutions in the embodiments are described clearly and completely below. Obviously, the embodiments described below are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] It should be understood that when used in this specification and the appended claims, the terms "include" and "comprises" indicate the presence of described features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or combinations thereof.

[0032] It should also be understood that the terms used in this description of the embodiments of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the embodiments of the present invention. As used in the description of the embodiments of the present invention and the appended claims, unless the context clearly indicates otherwise, the singular forms of "a", "an" and "the" are intended to include plural forms.

[0033] It should be noted that, in the following examples, unless otherwise specified, "%" in the components refers to volume percentage.

[0034] The embodiment of the present invention provides a hepatitis C virus liquid calibrant diluent, comprising the following components: 40-60mmoL / L buffer, 5.3-10.6g / L 2-morpholineethanesulfonic acid, 20-40% protein protective agent, 20-50g / L non-reducing disaccharide, 20-50g / L amino acid, 5-10% fetal bovine serum, 0.05-0.1% nonionic surfactant and 0.05-0.2% PC300.

[0035] The embodiment of the present invention also provides a method for preparing the above-mentioned hepatitis C virus liquid calibrator diluent, comprising the following steps:

[0036] At room temperature (25°C±3°C), using purified water as solvent, a buffer solution is prepared according to the formula concentration; 2-morpholineethanesulfonic acid is added thereto and dissolved; non-reducing disaccharides and amino acids are added and dissolved; fetal bovine serum is added and dissolved; non-ionic surfactant is added and dissolved; protein protective agent is added and dissolved; PC300 is added and fully stirred and mixed for 30 minutes after dissolution, and the pH of the solution is adjusted to 6-8, preferably 7.2-7.8, and more preferably 7.4±0.05, using 2mol / L hydrochloric acid or 1mol / L sodium hydroxide; finally, purified water is added to make up to the formula amount, stirred and mixed for 10 minutes, the final pH is measured and adjusted according to the measurement situation, stirred again for 10 minutes, allowed to stand for 30 minutes, and filtered using a nylon filter membrane with a pore size of 0.2-0.5μm to obtain the hepatitis C virus liquid calibrant dilution.

[0037] The prepared hepatitis C virus liquid calibrator dilution should be stored at 2-8℃.

[0038] The specific composition of the hepatitis C virus liquid calibrator diluent provided in Examples 1-16 of the present invention is shown in Table 1.

[0039] Unless otherwise specified, the PB buffer involved in the following examples is composed of 14.51 g / L disodium hydrogen phosphate and 1.48 g / L sodium dihydrogen phosphate; the sodium citrate buffer is composed of 0.69 g / L citric acid monohydrate and 4.82 g / L sodium citrate dihydrate; and the Tris buffer is prepared from 6.06 g / L Tris.

[0040] The protein protectant in the following examples is AP-Protector.

[0041] The nonionic surfactant used in the following examples is Tween 20.

[0042] Table 1 Hepatitis C virus liquid calibrator dilution formula provided in Examples 1-14

[0043]

[0044] The embodiment of the present invention also provides a hepatitis C liquid calibrator, specifically, adding a hepatitis C antigen to the hepatitis C liquid calibrator diluent prepared in the above embodiment to prepare a corresponding concentration, that is, obtaining a calibrator for a hepatitis C detection kit (chemiluminescence method).

[0045] Experiment 1

[0046] The stability of the hepatitis C liquid calibrator prepared from the hepatitis C liquid calibrator diluents of Examples 1-16 was investigated.

[0047] Hepatitis C antigen was added to the dilution obtained in Example 1-16 to prepare 5 calibration samples with different concentration gradients (called S0-S4). Then, each set of calibration samples was stored at 37°C for 8 days and compared with the corresponding calibration samples stored at 2-8°C to evaluate the signal retention rate of the luminescence value. The results are shown in Table 2.

[0048] Table 2 Effect of different embodiments of preparing hepatitis C virus liquid calibrator diluent on the stability of hepatitis C virus liquid calibrator

[0049]

[0050]

[0051]

[0052] Note 1: S0 is not included in the mean calculation.

[0053] Note 2: Signal retention rate (%) = luminescence value after acceleration at 37°C / luminescence value stored at 4°C*100%.

[0054] From the results in Table 2, it can be seen that the hepatitis C virus liquid calibrant diluent provided in the embodiment of the present invention is compounded with specific concentrations of 2-morpholineethanesulfonic acid, protein protectant AP-Protector, fetal bovine serum, trehalose, and glycine in a PB buffer system or a sodium citrate buffer system, and accelerated at 37° C. for 7 days. The signal retention rate is between 90-110%, among which the liquid calibrant diluent of Example 9 can achieve the best signal retention rate.

[0055] From the results of Example 1 and Example 9, the absence of trehalose, glycine and fetal bovine serum has a great influence on the stability of the whole system, and the addition of trehalose, glycine and fetal bovine serum can increase the signal retention rate of the system from 78% to more than 95%.

[0056] From the results of Examples 2-3, 14 and Example 9, 2-morpholineethanesulfonic acid, protein protective agent and buffer system have a great influence on the stability of the whole system. The lack of any component of 2-morpholineethanesulfonic acid and protein protective agent, or the use of Tris buffer, will seriously affect the stability of the system.

[0057] From the results of Examples 4-5 and Example 9, it can be seen that the liquid calibrant diluent provided by the present invention can use PB buffer or sodium citrate buffer as the buffer system. At the same time, the addition of fetal bovine serum can increase the signal retention rate of the system from 80% to more than 95%.

[0058] From the results of Examples 6-8 and 9, the hepatitis C virus liquid calibrant diluent provided by the present invention can best improve the stability of the system under the compounding of specific components, and the reduction of any one component of trehalose and amino acids has an impact on the stability of the system. The addition of trehalose and amino acids can increase the signal retention rate of the system from 80% to more than 95%.

[0059] From the results of Example 9 and Examples 10, 11, 12, and 13, the concentration of the protein protectant and the concentration of trehalose in the system will also affect the stability of the system. Among them, the concentration of the protein protectant in Example 11 is too low, only 10%, which has a greater impact on the stability of the system. In the hepatitis C virus liquid calibrator diluent of the present invention, the concentration of the protein protectant is recommended to be 20-40%, and the concentration of trehalose (non-reducing sugar) is recommended to be 20-50 g / L.

[0060] From the results of Example 9 and Examples 15 and 16, the effect of the pH of the system on the stability cannot be ignored. The pH at 7.4±0.05 can have the best signal retention rate, that is, the best stability, while too high or too low will reduce the stability. In the dilution solution of the hepatitis C liquid calibrator of the present invention, the pH of the system is recommended to be 7.4±0.05.

[0061] In summary, the effects of 2-morpholineethanesulfonic acid, protein protectant and buffer system, trehalose, glycine and fetal bovine serum on the stability of the system are not a simple linear superposition. The above components have the characteristics of mutual influence and interaction in the system. Only under the specific formula composition of the present invention can the optimal stability effect be achieved: under the conditions of PB buffer system or sodium citrate buffer system, 2-morpholineethanesulfonic acid 6-11g / L, protein protectant AP-Protector 20-40%, fetal bovine serum 5-10%, trehalose 20-50g / L, glycine 20-50g / L, non-ionic surfactant 0.05-0.1%, PC30000.05-0.1% combination can effectively improve the stability of hepatitis C liquid calibrator.

[0062] Experiment 2

[0063] The storage stability of the hepatitis C liquid calibrator prepared from the hepatitis C liquid calibrator diluent of Example 9 was investigated.

[0064] Hepatitis C antigen was added to the dilution obtained in Example 9, and 7 portions of each of 5 concentration gradient calibrants (called S0~S4) were prepared, and stored in sealed containers at 2-8℃ and -80℃. One portion was taken out at 0 month, 1 month, 2 months, 3 months, 6 months, 9 months, and 12 months respectively for comparison of the two storage conditions, and the signal retention rate of the luminescence value was evaluated. The results are shown in Table 3.

[0065] Table 3 Storage stability results of the hepatitis C virus liquid calibrator prepared in Example 9

[0066]

[0067] Note 1: S0 is not included in the mean calculation.

[0068] Note 2: Signal retention rate (%) = luminescence value after acceleration at 37°C / luminescence value stored at 4°C*100%.

[0069] From the results in Table 3, it can be seen that the calibrators provided in the embodiments of the present invention are stored at 2-8°C for 12 months, and the test signal retention rate is between 90% and 110%, indicating that the calibrators have good stability.

[0070] Experiment 3

[0071] The stability of the hepatitis C liquid calibrator prepared with the hepatitis C liquid calibrator diluent of Example 9 was compared with that of the hepatitis C liquid calibrator prepared with the conventional PBS calibrator diluent.

[0072] Comparative Example 1: Conventional PBS calibrant dilution solution, composed as follows: 50mmoL / LPB buffer, 10g / L sodium chloride, 0.1% Tween 20 and 0.1% PC300, pH 7.4±0.05.

[0073] The two dilutions prepared above were added with hepatitis C antigen to prepare five concentration gradient calibrators (called S0-S4), and then each set of calibrators was stored at 37°C for 8 days. The signal retention rate of the luminescence value was evaluated by comparing with the corresponding calibrators stored at 2-8°C. The results are shown in Table 4.

[0074] Table 4 Stability results of the calibrators prepared with the calibrator dilutions of Example 9 and Comparative Example 1

[0075]

[0076] Note 1: S0 is not included in the mean calculation.

[0077] Note 2: Signal retention rate (%) = luminescence value after acceleration at 37°C / luminescence value stored at 4°C*100%.

[0078] It can be seen from the results in Table 4 that the hepatitis C virus liquid calibrant diluent used in the present invention, compared with the conventional PBS diluent, adds 2-morpholineethanesulfonic acid, protein protectant, non-reducing disaccharide, amino acid and fetal bovine serum, which significantly improves the stability of the prepared calibrant.

[0079] In the above embodiments, the description of each embodiment has its own emphasis. For parts that are not described in detail in a certain embodiment, reference can be made to the relevant descriptions of other embodiments.

[0080] The above is a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of various equivalent modifications or replacements within the technical scope disclosed by the present invention, and these modifications or replacements should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.

Claims

1. A hepatitis C virus liquid calibrator diluent, characterized in that: Includes the following ingredients: 40-60mmoL / L buffer, 5.3-10.6g / L 2-morpholineethanesulfonic acid, 20-40% (v / v) protein protectant, 20-50g / L non-reducing disaccharide, 20-50g / L amino acid, 5-10% bovine serum.

2. The hepatitis C virus liquid calibrator diluent according to claim 1, characterized in that: The protein protector includes AP-Protector.

3. The hepatitis C virus liquid calibrator diluent according to claim 1, characterized in that: The buffer is selected from at least one of PB buffer and sodium citrate buffer.

4. The hepatitis C virus liquid calibrator diluent according to claim 1, characterized in that: The bovine serum is selected from fetal bovine serum.

5. The hepatitis C virus liquid calibrator diluent according to claim 1, characterized in that: The invention also comprises 0.05-0.1% by volume of a nonionic surfactant and 0.05-0.2% by volume of a preservative.

6. The hepatitis C virus liquid calibrator diluent according to claim 1, characterized in that: The pH of the hepatitis C virus liquid calibrant diluent is 7.0-8.

0.

7. The hepatitis C virus liquid calibrator diluent according to claim 6, characterized in that: The pH of the hepatitis C virus liquid calibrant diluent is 7.2-7.

8.

8. A method for preparing a hepatitis C virus liquid calibrator diluent according to any one of claims 1 to 7, characterized in that: The method comprises dissolving and mixing the components in proportion, and then diluting the mixture to the prepared amount with purified water, filtering the mixture with a filter membrane having a pore size of 0.2-0.5 μm, so as to obtain the hepatitis C virus liquid calibrant diluent.

9. A liquid calibrator for hepatitis C virus, characterized in that: It comprises hepatitis C antigen, and the hepatitis C virus liquid calibrator diluent as described in any one of claims 1 to 7 or the hepatitis C virus liquid calibrator diluent obtained by the preparation method according to claim 8.

10. A hepatitis C virus detection kit, characterized in that: Including the hepatitis C virus liquid calibrator as described in claim 9.

Citation Information

Cited By

  • Composition, protein control substance matrix liquid containing composition, CHI3L1 quality control substance, CHI3L1 detection kit and detection method

    CN120142675A

  • Composition, protein control substrate solution containing the same, CHI3L1 control, CHI3L1 detection kit and detection method

    CN120142675B